Vericel Corporation
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the … Read more
Market Cap & Net Worth: Vericel Corporation (ATQP)
Vericel Corporation (F:ATQP) has a market capitalization of $1.43 Billion (€1.40 Billion) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #6025 globally and #635 in its home market, demonstrating a -3.50% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Vericel Corporation's stock price €27.60 by its total outstanding shares 50574026 (50.57 Million).
Vericel Corporation Market Cap History: 2015 to 2026
Vericel Corporation's market capitalization history from 2015 to 2026. Data shows growth from $118.83 Million to $1.43 Billion (28.15% CAGR).
Vericel Corporation Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Vericel Corporation's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
11.93x
Vericel Corporation's market cap is 11.93 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
273.04x
Vericel Corporation's market cap is 273.04 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $118.83 Million | $51.17 Million | -$16.34 Million | 2.32x | N/A |
| 2016 | $150.86 Million | $54.38 Million | -$19.57 Million | 2.77x | N/A |
| 2017 | $223.23 Million | $63.92 Million | -$17.29 Million | 3.49x | N/A |
| 2018 | $711.73 Million | $90.86 Million | -$8.14 Million | 7.83x | N/A |
| 2019 | $807.24 Million | $117.85 Million | -$9.66 Million | 6.85x | N/A |
| 2020 | $1.24 Billion | $124.18 Million | $2.86 Million | 9.98x | 432.67x |
| 2021 | $1.87 Billion | $156.18 Million | -$7.47 Million | 11.97x | N/A |
| 2022 | $1.23 Billion | $164.37 Million | -$16.71 Million | 7.46x | N/A |
| 2023 | $1.68 Billion | $197.52 Million | -$3.18 Million | 8.52x | N/A |
| 2024 | $2.83 Billion | $237.22 Million | $10.36 Million | 11.93x | 273.04x |
Competitor Companies of ATQP by Market Capitalization
Companies near Vericel Corporation in the global market cap rankings as of March 18, 2026.
Key companies related to Vericel Corporation by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Vericel Corporation Historical Marketcap From 2015 to 2026
Between 2015 and today, Vericel Corporation's market cap moved from $118.83 Million to $ 1.43 Billion, with a yearly change of 28.15%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €1.43 Billion | -13.21% |
| 2025 | €1.65 Billion | -41.65% |
| 2024 | €2.83 Billion | +68.21% |
| 2023 | €1.68 Billion | +37.23% |
| 2022 | €1.23 Billion | -34.42% |
| 2021 | €1.87 Billion | +50.82% |
| 2020 | €1.24 Billion | +53.50% |
| 2019 | €807.24 Million | +13.42% |
| 2018 | €711.73 Million | +218.84% |
| 2017 | €223.23 Million | +47.97% |
| 2016 | €150.86 Million | +26.96% |
| 2015 | €118.83 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Vericel Corporation was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.43 Billion USD |
| MoneyControl | $1.43 Billion USD |
| MarketWatch | $1.43 Billion USD |
| marketcap.company | $1.43 Billion USD |
| Reuters | $1.43 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.